Exelixis (EXEL) investor relations material

Strategic overview and financial performance

• Lead molecule CABOMETYX (cabozantinib) is approved for multiple cancers and underpins research and strategy.

• Achieved $2.123 billion in net product sales last year, with guidance of ~$2.4 billion for this year.

• Financial strength supports internal/external investments and share buybacks.

Pipeline development and clinical progress

• Zanzalintinib, a next-generation TKI, is in seven pivotal studies with a PDUFA date in December.

• Internal portfolio includes both small molecules and biotherapeutics.

• Expansion into adjuvant CRC with STELLAR-316, leveraging ctDNA testing to identify high-risk patients.

Commercial strategy and market positioning

• Focused on solid tumors, especially GI and GU oncology, aiming for a balanced 50/50 split.

• Increased sales force to maximize NET and prepare for CRC launches.

• Uses a disciplined approach to external opportunities, prioritizing programs with potential to set new standards of care.